Advaxis, Inc. Business Finance Contracts & Agreements
130 Contracts & Agreements
- Debenture Agreements (1 contract)
- Exchange Agreements (7)
- Investment Agreements (1)
- Note Agreements (30)
- Purchase Agreements (12)
- Registration Rights Agreements (11)
- Release Agreements (1)
- Security Agreements (5)
- Stock Agreements (9)
- Subordination Agreement (1)
- Underwriting Agreements (10)
- Warrant Agreements (42)
- Common Stock Purchase Warrant (Convertible Note), dated March 1, 2024, issued by Ayala Pharmaceuticals, Inc. to Israel Biotech Fund I, L.P (Filed With SEC on March 5, 2024)
- Senior Convertible Promissory Note, dated March 1, 2024, by and between Ayala Pharmaceuticals, Inc. and Israel Biotech Fund I, L.P (Filed With SEC on March 5, 2024)
- Asset Purchase Agreement, dated as of February 5, 2024, by and between Ayala Pharmaceuticals, Inc. and Immunome, Inc (Filed With SEC on February 6, 2024)
- Registration Rights Agreement, dated November 17, 2023, by and among Ayala Pharmaceuticals, Inc., Israel Biotech Fund I, L.P., Israel Biotech Fund II, L.P., Arkin Bio Ventures... (Filed With SEC on November 20, 2023)
- Subordination Agreement, dated November 17, 2023, by and among Ayala Pharmaceuticals, Inc., Israel Biotech Fund I, L.P. and Israel Biotech Fund II, L.P., Arkin Bio Ventures L.P.... (Filed With SEC on November 20, 2023)
- Side Letter Agreement (New Notes), dated November 17, 2023, by and among Ayala Pharmaceuticals, Inc., Israel Biotech Fund I, L.P., Israel Biotech Fund II, L.P., Arkin Bio Ventures... (Filed With SEC on November 20, 2023)
- Common Stock Purchase Warrant (Secured Note), dated November 17, 2023, issued by Ayala Pharmaceuticals, Inc. to Israel Biotech Fund I, L.P (Filed With SEC on November 20, 2023)
- Common Stock Purchase Warrant (Convertible Note), dated November 17, 2023, issued by Ayala Pharmaceuticals, Inc. to Israel Biotech Fund I, L.P (Filed With SEC on November 20, 2023)
- Senior Convertible Promissory Note, dated November 17, 2023, by and between Ayala Pharmaceuticals, Inc. and Israel Biotech Fund I, L.P (Filed With SEC on November 20, 2023)
- Amended and Restated Senior Secured Convertible Promissory Note, dated November 17, 2023, by and between Ayala Pharmaceuticals, Inc. and Israel Biotech Fund I, L.P (Filed With SEC on November 20, 2023)
- Security Agreement, dated August 7, 2023, by and between Ayala Pharmaceuticals, Inc. and Israel Biotech Fund I, L.P (Filed With SEC on August 10, 2023)
- Senior Secured Convertible Promissory Note, dated August 7, 2023, by and between Ayala Pharmaceuticals, Inc. and Israel Biotech Fund I, L.P (Filed With SEC on August 10, 2023)
- Subscription and Investment Representation Agreement, dated December 1, 2022, by and between Advaxis, Inc. and the purchaser signatory thereto (Filed With SEC on December 2, 2022)
- Form of Warrant (Filed With SEC on June 13, 2022)
- Form of Warrant (Filed With SEC on May 24, 2022)
- Form of Underwriting Agreement (Filed With SEC on May 24, 2022)
- Form of Registration Rights Agreement by and among Advaxis, Inc. and the investors named therein (Filed With SEC on January 28, 2022)
- Form of Securities Purchase Agreement between Advaxis, Inc. and the investors thereto, dated January 27, 2022 (Filed With SEC on January 28, 2022)
- Form of Registration Rights Agreement (Filed With SEC on November 9, 2021)
- Form of Securities Purchase Agreement (Filed With SEC on November 9, 2021)
- Securities Purchase Agreement dated April 12, 2021, by and among Advaxis, Inc. and the purchasers identified on the signature pages thereto (Filed With SEC on April 12, 2021)
- Form of Private Placement Warrant (Filed With SEC on April 12, 2021)
- Form of Accompanying Warrant (Filed With SEC on April 12, 2021)
- Form of Pre-Funded Warrant (Filed With SEC on April 12, 2021)
- Form of Warrant Exchange Agreement, dated October 16, 2020 (Filed With SEC on January 22, 2021)
- Form of Warrant (Filed With SEC on November 27, 2020)
- Underwriting Agreement, dated as of November 24, 2020, by and between Advaxis, Inc. and A.G.P./Alliance Global Partners (Filed With SEC on November 27, 2020)
- Rights Agreement, dated as of September 29, 2020, by and between Advaxis, Inc. and Continental Stock Transfer and Trust Company, as rights agent (Filed With SEC on September 29, 2020)
- Purchase Agreement, dated July 30, 2020, by and between Advaxis, Inc. and Lincoln Park Capital Fund, LLC (Filed With SEC on August 3, 2020)
- Registration Rights Agreement, dated July 30, 2020, by and between Advaxis, Inc. and Lincoln Park Capital Fund, LLC (Filed With SEC on August 3, 2020)
- Securities Purchase Agreement dated January 21, 2020, by and among Advaxis, Inc. and the purchasers identified on the signature pages thereto (Filed With SEC on January 23, 2020)
- Form of Warrant (Filed With SEC on January 23, 2020)
- Form of Exchange Agreement dated March 14, 2019 (Filed With SEC on September 9, 2019)
- Warrant Agency Agreement, entered into by Advaxis, Inc. on July 25, 2019 with Continental Stock Transfer and Trust Company (Filed With SEC on July 25, 2019)
- Underwriting Agreement, entered into by Advaxis, Inc. on July 23, 2019 with A.G.P./ Alliance Global Partners (Filed With SEC on July 25, 2019)
- Form of Warrant Agency Agreement, between Advaxis, Inc. and Continental Stock Transfer and Trust Company (Filed With SEC on July 22, 2019)
- Form of Underwriting Agreement (Filed With SEC on July 22, 2019)
- Form of Warrant Agency Agreement, between Advaxis, Inc. and Continental Stock Transfer and Trust Company (Filed With SEC on July 17, 2019)
- Form of Underwriting Agreement (Filed With SEC on July 17, 2019)
- Form of Exchange Agreement dated March 14, 2019 (Filed With SEC on June 10, 2019)
